Leerink Partners analyst Thomas Smith maintained a Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) Inc on Tuesday, setting a price target of $145, which is approximately 29.33% above the present share price of $112.12.
Smith expects Madrigal Pharmaceuticals Inc to post earnings per share (EPS) of -$3.82 for the first quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Moderate Buy rating of shares in Madrigal Pharmaceuticals, with an average price target of $170.58.
The analysts price targets range from a high of $225 to a low of $126.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$59.56 million. The company's market cap is $1.8 billion.
According to TipRanks.com, Leerink Partners analyst Thomas Smith is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 1.0% and a 38.10% success rate.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.